The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Roy D. Baynes, MD, PhD, to Join Gilead Sciences as Senior Vice President, Oncology Therapeutics

Wednesday, January 18, 2012

Roy D. Baynes, MD, PhD, to Join Gilead Sciences as Senior Vice President, Oncology Therapeutics16:40 EST Wednesday, January 18, 2012 FOSTER CITY, Calif. (Business Wire) -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Roy D. Baynes, MD, PhD, will join the company as Senior Vice President, Oncology Therapeutics. In this position, Dr. Baynes will report to Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer and will have responsibility for Gilead's programs in oncology. Dr. Baynes will also join Gilead's Executive Committee. “Roy's appointment reflects our commitment to building a leading oncology research and development program, and I am very pleased to welcome him to the Gilead team,” said Dr. Bischofberger. “Roy has an extensive background in clinical practice, academic research and in cancer drug development. Under his leadership, we are well positioned to advance our growing number of pipeline programs targeted at both hematological malignancies and solid tumors.” Dr. Baynes joins Gilead from Amgen, where he served as Vice President, Global Development and Therapeutic Area Head Hematology Oncology. He led the Clinical Development and Medical Affairs teams responsible for the approval and/or launch of numerous hematology and oncology products over the last decade. Prior to joining Amgen in 2002, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit, where he also held the positions of Professor of Medicine, Professor of Oncology and Director of the Bone Marrow Transplant Program. “I've long admired Gilead's scientific approach and am excited to join the company at a time when it is rapidly building its presence in oncology through acquisitions and innovative partnerships,” said Dr. Baynes. “Cancer research is an incredibly challenging and evolving field, but one with great opportunity and I look forward to working closely with the internal team and external collaborators as we seek to develop novel cancer therapies that address significant unmet medical needs.” Dr. Baynes received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa, and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital. He is a member or fellow of several medical societies and has published more than 200 peer-reviewed articles and abstracts. About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Gilead Sciences, Inc.Susan Hubbard, 650-522-5715 (Investors)Nathan Kaiser, 650-522-1853 (Media)